Микробиологические аспекты диагностики хронического простатита

Клиническая Микробиология и Антимикробная Химиотерапия. 2006; 8(1):4-17

​ Набер К., Сухорукова М.В.
хронический простатит синдром хронической тазовой боли проба Meares-Stamey микробиологическая диагностика колонизация инфекция
Раздел
Болезни и возбудители
Тип
Журнальная статья
Публикация
Клиническая Микробиология и Антимикробная Химиотерапия. 2006; 8(1):4-17

Аннотация

Хронический простатит/синдром хронической тазовой боли является одним из наиболее распространённых и трудных для диагностики и лечения заболеваний в урологической практике. Согласно современным международным рекомендациям, выбор подходов к терапии хронического простатита зависит от локализации патологического процесса в моче­выводящих путях, клинической формы, а также этиологии заболевания. В данной статье представлены современные аспекты микробиологической диагностики хронического простатита, а также вопросы эпидемиологии и классификации данного заболевания. Также обсуждается роль грамположительных возможных патогенов в качестве возбудителей хронического простатита.

  • 1. Krieger J.N. Classification, epidemiology and implications of chronic prostatitis in North America, Europe and Asia. Minerva Urol Nefrol 2004; 56:99-107.
  • 2. Nickel C.J. Prostatitis: evolving management strategies. Urol Clin North Am 1999; 26:737-57.
  • 3. Meares E.M., Stamey T.A. Bacteriologic localization patterns in bacterial prostatitis and urethritis. Invest Urol 1968; 5:492-518.
  • 4. Moon T.D. Questionnaire survey of urologists and primary care physicians’ diagnostic and treatment practices for prostatitis. Urology 1997; 50:543-7.
  • 5. Roberts R.O., Jacobson D.J., Girman C.J., et al. Prevalence of prostatitis-like symptoms in a community based cohort of older men. J Urol 2002; 168:2467-71.
  • 6. Alexander R.B. Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome. Ann Intern Med 2004; 141:581-9.
  • 7. Nickel J.C., Downey J., Hunter D., Clark J. Prevalence of prostatitis-like symptoms in a population based study using the National Institutes of Health chronic prostatitis symptom index. J Urol 2001; 165:842-5.
  • 8. Collins M.M., Stafford R.S., O’Leary M.P., Barry M.J. How common is prostatitis? A national survey of physician visits. J Urol 1998; 159:1224-8.
  • 9. Boyle P., Robertson C., Mazetta C., et al.; UrEpik Study Group. The prevalence of lower urinary tract symptoms in men and women in four centres. The UrEpik study. BJU Int 2003; 92:409-14.
  • 10. Rizzo M., Marchetti F., Travaglini F., et al. Prevalence, diagnosis and treatment of prostatitis in Italy: a prospective urology outpatient practice study. BJU Int 2003; 92:955-9.
  • 11. Naber K.G., Weidner W. Chronic prostatitis – an infectious disease? J Antimicrob Chemother 2000; 46:157-61.
  • 12. Krieger J.N., Egan K.J., Ross S.O., et al. Chronic pelvic pains represent the most prominent urogenital symptoms of «chronic prostatitis». Urology 1996; 48:715-22.
  • 13. European Association of Urology. Guidelines on chronic pelvic pain, 2003. Available from www.uroweb.org.
  • 14. Набер К. Оптимальная терапия инфекций мочевыводящих путей. Клиническая Микробиология и Антимикробная Химиотерапия 1999; 1:23-30.
  • 15. Weidner W., Schiefer H.G., Krauss H., et al. Chronic prostatitis: a thorough search for etiologically involved microorganisms in 1461 patients. Infection 1991; 19(Suppl. 3): S119-S125.
  • 16. Naber K.G. Chronic (Bacterial) Prostatitis. Lectures in Hospital Infections. Part Two: Complicated Urinary Tract Infections. London: 2003. P. 13-31.
  • 17. Drach G.W., Fair W.R., Meares E.M., Stamey T.A. Classification of benign diseases associated with prostatic pain: prostatitis or prostatodynia? J Urol 1978; 120:266.
  • 18. Lummus W.E., Thompson I. Prostatitis. Emerg Med Clin North Am 2001; 19:691-707.
  • 19. Nickel J.C., Weidner W. Chronic Prostatitis: Current Concepts and Antimicrobial Therapy. Infect Urol 2000; 13(Suppl.):22-8.
  • 20. Nickel J.C. Prostatitis: myths and realities. Urology 1998; 51:362-6.
  • 21. Krieger J.N., Nyberg L.M., Nickel J.C. for the International Prostatitis Collaborative Network. NIH consensus definition and classification of prostatitis. JAMA 1999; 282:236-7.
  • 22. National Institutes of Health. Summary Statement. National Institutes of Health/National Institutes of Diabetes and Digestive and Kidney Diseases workshop on chronic prostatitis. Bethesda, USA. 1995.
  • 23. Nickel J.C. Prostatitis: lessons from the 20th century. Br J Urol 2000; 85:179-84.
  • 24. Domingue G.J. Sr., Hellstrom W.J. Prostatitis. Clin Microbiol Rev 1998; 11:604-13.
  • 25. Naber K.G. The role of quinolones in the treatment of chronic bacterial prostatitis. Infection 1991; 19(Suppl. 3):S170-S177.
  • 26. Nickel J.C. Chronic prostatitis: an infectious disease? Infect Urol 2000; 13:31-8.
  • 27. Bundrick W., Heron S.P., Ray P., et al. Levofloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis: a randomized double-blind multicenter study. Urology 2003; 62:537-41.
  • 28. Nickel J.C., Costerton J.W. Coagulase-negative staphylococcus in chronic prostatitis. J Urol 1992; 147:398-400.
  • 29. Domingue G.J. Microbiological aspects of prostatitis. In: Textbook on prostatitis. Oxford: ISIS Medical Media Ltd.; 1999. P. 69-81.
  • 30. Stamey T.A. Comment to Fawler&Mariano. J Urol 1984; 132:471-3.
  • 31. Arakawa S., Matsui T., Gohji K., et al. Prostatitis – the Japanese viewpoint. Int J Antimicrob Agents 1999; 11:201-3.
  • 32. Naber K.G. Prostatitis, Epididymitis and Orchitis. London: Mosby; 1999. p. 58.1-58.6.
  • 33. Nickel J.C. The Pre and Post Massage Test (PPMT): a simple screen for prostatitis. Tech Urol 1997; 3:38-43.
  • 34. Nickel J.C. Prostatitis. Is it time to change the rules? Contemporary urology 2000: 64-84.
  • 35. Schaeffer A.J., Wendel E.F., Dunn J.K., Grayhack J.T. Prevalence and significance of prostatic inflammation. J Urol 1981; 125:215-9.
  • 36. Nickel J.C., Alexander R.B., Schaeffer A.J., et al. Leukocytes and bacteria in men with chronic prostatitis/ chronic pelvic pain syndrome compared to asymptomatic controls. J Urol 2003; 170:818-22.
  • 37. Li L.J., Shen Z.J., Lu Y.L., Fu S.Z. The value of endotoxin concentrations in expressed prostatic secretions for the diagnosis and classification of chronic prostatitis. BJU Int 2001; 88:536-9.
  • 38. Wagenlehner F.M., Weidner W., Sorgel F., Naber K. The role of antibiotics in chronic bacterial prostatitis. Int J Antimicrob Agents 2005; 26:1-7.
  • 39. Nickel J.C. Classification and diagnosis of prostatitis: a gold standard? Andrologia 2003; 35:160-7.
  • 40. Nickel J.C., Moon T. Chronic bacterial prostatitis: an evolving clinical enigma. Urology 2005; 66:2-8.
  • 41. Andreu A., Stapleton A.E., Fennell C., et al. Urovirulence determinants in Escherichia coli strains causing prostatitis. J Infect Dis 1997; 176:464-9.
  • 42. Naber K.G. Lomefloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis. Int J Antimicrob Agents 2002; 20:18-27.
  • 43. Naber K.G., Busch W., Focht J. Ciprofloxacin in the treatment of chronic bacterial prostatitis: a prospective, non-comparative multicentre clinical trial with long-term follow-up. The German Prostatitis Study Group. Int J Antimicrob Agents 2000; 14:143-9.
  • 44. Krieger J.N., Ross S.O., Limaye A.P., Riley D.E. Inconsistent localization of gram-positive bacteria to prostate-specific specimens from patients with chronic prostatitis. Urology 2005; 66:721-5.
  • 45. Krieger J.N., Riley D.E. Bacteria in the chronic prostatitis-chronic pelvic pain syndrome: molecular approaches to critical research questions. J Urol 2002; 167:2574-83.
  • 46. Krieger J.N., Riley D.E., Roberts M.C., Berger R.E. Prokaryotic DNA sequences in patients with chronic idiopathic prostatitis. J Clin Microbiol 1996; 34:3120-8.
  • 47. Skerk V., Krhen I., Lisic M., et al. 4.5- or 6.0-gram dose in the treatment of patients with chronic prostatitis caused by Chlamydia trachomatis – a randomized study. J Chemother 2004; 16:408-10.
  • 48. Skerk V., Schonwald S., Krhen I., et al. Comparative analysis of azithromycin and ciprofloxacin in the treatment of chronic prostatitis caused by Chlamydia trachomatis. Int J Antimicrob Agents 2003; 21:457-62.
  • 49. Skerk V., Schonwald S., Krhen I., et al. Aetiology of chronic prostatitis. Int J Antimicrob Agents 2002; 19:471-4.
  • 50. Smelov V., Perekalina T., Artemenko N., et al. Chlamydia trachomtis survival in the presence of two fluoroqinolones (lomefloxacin versus levofloxacin) on patients with chronic prostatitis syndrome. Andrologia 2005; 37:61-4.
  • 51. Domingue G.J., Human L.G., Hellstrom W.J. Hidden microorganisms in “abacterial” prostatitis/prostatodinia. J Urol 1997; 157:952.
  • 52. Riegel P., Ruimy R., de Briel D., et al. Corynebacterium seminale sp. nov., a new species associated with genital infections in male patients. J Clin Microbiol 1995; 33:2244-9.
  • 53. Benson P.J. Cytomеgalovirus prostatitis. Urology 1992; 40:165-7.
  • 54. Doble A., Harris J.R., Taylor-Robinson D. Prostatodynia and herpes simplex virus infection. Urology 1991; 38:247-8.
  • 55. Shortliffe L.M., Sellers R.G., Schachter J. The characterization of nonbacterial prostatitis: search for an etiology. J Urol 1992; 148:1461-6.
  • 56. Ostaszewska I. Chlamydia trachomatis as a probable cause of prostatitis. Int J STD/AIDS 2000; 11:482-3.
  • 57. Mardh P.A., Ripa K.T., Colleen S., et al. Role of Chlamydia trachomatis in non-acute prostatitis. Br J Vener Dis 1978; 54:330-4.
  • 58. National guideline for the management of prostatitis. Clinical Effectiveness Group (Association of Genitourinary Medicine and the Medical Society for the Study of Venereal Diseases). Sex Transm Infect 1999; 75(Suppl. 1):S46-S50.
  • 59. Krieger J.N., Ross S.O., Berger R.E., Riley D.E. Cryptic microorganisms and prostatitis. In: Textbook on prostatitis. 1999. p. 139-148.
  • 60. Skerk V., Schonwald S., Krhen I., et al. Comparative analysis of azithromycin and clarithromycin efficacy and tolerability in the treatment of chronic prostatitis caused by Chlamydia trachomatis. J Chemother 2002; 14:384-9.
  • 61. Skerk V., Schonwald S., Krhen I., et al. Azithromycin in the treatment of chronic prostatitis caused by Chlamydia trachomatis. J Chemother 2001; 13:664-5.
  • 62. Smelov V., Gorelov A., Smelova N., Krylova T. Single-drug or combined antibacterial therapy in the treatment of patients with chronic prostatitis and Chlamydia trachomatis? Int J Antimicrob Agents 2004; 23(Suppl. 1): S83-S87.
  • 63. Weidner W., Diemer T., Huwe P., et al. The role of Chlamydia trachomatis in prostatitis. Int J Antimicrob Agents 2002; 19:466-70.
  • 64. Krieger J.N., Riley D.E. Prostatitis: what is the role of infection. Int J Antimicrob Agents 2002; 19:475-9.
  • 65. Potts J.M., Sharma R., Pasqualotto F., et al. Association of Ureaplasma urealyticum with abnormal reactive oxygen species levels and absence of leukocytospermia. J Urol 2000; 163:1775-8.
  • 66. Ohkawa M., Yamaguchi K., Tokunaga S., et al. Ureaplasma urealyticum in the urogenital tract of patients with chronic prostatitis or related symptomatology. Br J Urol 1993; 72:918-21.
  • 67. Brook I. Urinary tract and genito-urinary suppurative infections due to anaerobic bacteria. Int J Urol 2004; 11:133-41.
  • 68. Nagy E., Szoke I., Torok L., Pajor L. The role of anaerobic bacteria in prostatitis. Adv Exp Med Biol 2000; 485:289-99.
Просмотров
0 Аннотация
0 PDF
0 Цитирования
Поделились